ANCA Vasculitis - Pipeline Insight, 2022

DelveInsight's, "ANCA Vasculitis - Pipeline Insight, 2022," report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in ANCA Vasculitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

• Global coverage

ANCA Vasculitis Understanding

ANCA Vasculitis: Overview

Antineutrophilic cytoplasmic antibody (ANCA) associated vasculitides are a heterogeneous group of rare autoimmune conditions that causes an inflammation of blood vessels with various manifestations. It includes three main diseases, which are granulomatosis with polyangiitis (GPA; formerly known as Wegener granulomatosis), eosinophilic granulomatosis with polyangiitis (EGPA; previously known as Churg-Strauss syndrome), and microscopic polyangiitis (MPA). Other ANCA-associated diseases are drug-induced vasculitis and renal limited vasculitis. The diagnosis of vasculitis needs a high index of suspicion because of the rarity of the disease and the multisystemic nature of vasculitis. A detailed history and physical examination are key in the management of vasculitis. A complete workup is required to establish the diagnosis, rule out other causes, and evaluate the severity of the disease and organ involvement. To establish the diagnosis, a combination of clinical assessment with serological testing is needed, and a tissue biopsy many times confirms the diagnosis.

"ANCA Vasculitis - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the ANCA Vasculitis pipeline landscape is provided which includes the disease overview and ANCA Vasculitis treatment guidelines. The assessment part of the report embraces, in depth ANCA Vasculitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, ANCA Vasculitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for ANCA Vasculitis.
• In the coming years, the ANCA Vasculitis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics that are working to assess challenges and seek opportunities that could influence ANCA Vasculitis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• A detailed portfolio of major pharma players who are involved in fueling the ANCA Vasculitis treatment market. Several potential therapies for ANCA Vasculitis are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the ANCA Vasculitis market size in the coming years.
• Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of ANCA Vasculitis) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

ANCA Vasculitis Emerging Drugs Chapters

This segment of the ANCA Vasculitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

ANCA Vasculitis Emerging Drugs

• Depemokimab: GlaxoSmithKline

Depemokimab (GSK'294) is an anti-IL-5 monoclonal antibody currently in development for the treatment of severe eosinophilic asthma. It is a distinct, new biologic entity and has been engineered for high affinity and long-acting suppression of IL-5 function. IL-5 is the major cytokine responsible for the proliferation, activation and survival of eosinophils, making it a proven treatment target for severe asthma patients with higher levels of eosinophils. Currently, it is in Phase III stage of clinical trial evaluation to treat Eosinophilic Granulomatosis with Polyangiitis.

• Benralizumab: AstraZeneca

Benralizumab is a humanized recombinant monoclonal antibody of the isotype IgG1k immunoglobulin that specifically binds to the alpha chain of the interleukin 5 receptor (IL-5R) expressed on eosinophils and basophils. It inhibits the binding of IL-5 as well as the hetero-oligomerization of the alpha and beta subunits of the IL-5R, thus blocking, signal transduction. Besides, it is an afucosylated IgG which gives it high affinity for the FcγRIIIα receptor in natural killer cells, macrophages and neutrophils.1 Benralizumab, FDA approved on November 14, 2017, was developed by MedImmune, the AstraZeneca's global biologic research and development arm. Currently, it is in Phase III stage of clinical trial evaluation to treat Eosinophilic Granulomatosis with Polyangiitis.

Further product details are provided in the report……..

ANCA Vasculitis: Therapeutic Assessment

This segment of the report provides insights about the different ANCA Vasculitis drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in ANCA Vasculitis

There are approx. 8+ key companies which are developing the therapies for ANCA Vasculitis. The companies which have their ANCA Vasculitis drug candidates in the most advanced stage, i.e. phase III include, GlaxoSmithKline.

• Phases

DelveInsight's report covers around 8+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

ANCA Vasculitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous
• Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

ANCA Vasculitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses ANCA Vasculitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging ANCA Vasculitis drugs.

ANCA Vasculitis Report Insights

• ANCA Vasculitis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

ANCA Vasculitis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing ANCA Vasculitis drugs?
• How many ANCA Vasculitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of ANCA Vasculitis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the ANCA Vasculitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for ANCA Vasculitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• GlaxoSmithKline
• AstraZeneca
• Staidson (Beijing) Biopharmaceuticals Co., Ltd
• Bristol-Myers Squibb
• InflaRx N.V.
• Chia Tai Tianqing Pharmaceutical
• Visterra

Key Products

• Depemokimab
• Benralizumab
• BDB-001
• Abatacept
• Vilobelimab
• Belimumab
• Meperizumab